1. Home
  2. ZION vs TGTX Comparison

ZION vs TGTX Comparison

Compare ZION & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zions Bancorporation N.A.

ZION

Zions Bancorporation N.A.

N/A

Current Price

$65.74

Market Cap

9.4B

Sector

Finance

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$56.12

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZION
TGTX
Founded
1873
1993
Country
United States
United States
Employees
N/A
399
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.4B
8.5B
IPO Year
2012
2008

Fundamental Metrics

Financial Performance
Metric
ZION
TGTX
Price
$65.74
$56.12
Analyst Decision
Hold
Strong Buy
Analyst Count
18
5
Target Price
$65.33
$49.80
AVG Volume (30 Days)
1.2M
1.7M
Earning Date
04-20-2026
05-04-2026
Dividend Yield
2.88%
N/A
EPS Growth
21.41
1746.67
EPS
4.61
0.17
Revenue
$662,000,000.00
$2,785,000.00
Revenue This Year
$8.57
$49.08
Revenue Next Year
$4.67
$26.69
P/E Ratio
$14.57
$329.40
Revenue Growth
3.60
N/A
52 Week Low
$46.21
$26.76
52 Week High
$73.34
$59.30

Technical Indicators

Market Signals
Indicator
ZION
TGTX
Relative Strength Index (RSI) 32.15 59.46
Support Level $58.17 $51.51
Resistance Level $66.18 $58.12
Average True Range (ATR) 1.48 2.21
MACD -0.18 -0.03
Stochastic Oscillator 0.25 76.89

Price Performance

Historical Comparison
ZION
TGTX

About ZION Zions Bancorporation N.A.

Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: